

GUJARAT INJECT (KERALA) LIMITED

CIN: L18100KL1991PLC005926

Regd Office: Bldg No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad – 678 621

Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara – 390 005

Phones: 09898593314, 09712193314

E-Mail: murlisnair9032@gmail.com, admin@gikl.com Website: www.gujaratinject.in

Date: February 10, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter ended on December 31, 2022 along with Limited Review Report.

Ref: Gujarat Inject Kerala Limited (Security ID: GUJINJEC, Security Code: 524238)

In reference to captioned subject and pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

1. Unaudited Financial Results for the quarter ended on December 31, 2022;
2. Limited Review Report.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Gujarat Inject Kerala Limited



Reena Mahatma
Non-Executive Director
DIN: 02846012

GUJARAT INJECT KERALA LIMITED

CIN : L18100KL1991PLC005926

Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621
Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, SayaJiganj , Vadodara - 390005

Statement of Financial Results for the Quarter ended on December 31, 2022

(₹ In Lakh except per share data)

Particulars	Quarter Ended			9 MONTH ENDED		Year Ended
	31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
A Date of start of reporting period	01-10-2022	01-07-2022	01-10-2021	01-04-2022	01-04-2021	01-04-2021
B Date of end of reporting period	31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
C Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
D Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
I Revenue From Operations						
Net sales or Revenue from Operations	10.04	3.21	1.19	17.38	2.26	2.26
II Other Income	-	40.00	0.26	40.24	0.52	4.82
III Total Income (I+II)	10.04	43.21	1.45	57.62	2.78	7.08
IV Expenses						
(a) Cost of materials consumed	-	2.99	0.99	6.18	1.93	(0.58)
(b) Purchases of stock-in-trade	9.20	-	-	9.20	-	2.13
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d) Employee benefit expense	0.36	0.36	0.36	1.08	0.74	1.43
(e) Finance Costs	-	-	-	-	3.00	-
(f) Depreciation and amortisation expense	-	-	-	-	-	-
(g) Other Expenses	0.15	36.18	0.12	36.43	0.24	3.81
(h) Manufacturing Expenses	-	-	-	-	-	-
(i) Sales & Promotion Expenses	-	-	-	-	-	-
(j) Administrative Expenses	-	-	-	-	-	-
Total expenses (IV)	9.71	39.53	1.47	52.89	5.91	6.79
V Profit/(loss) before exceptional items and tax (III-IV)	0.33	3.68	(0.02)	4.73	(3.13)	0.29
VI Exceptional items						
VII Profit (loss) after exceptional items and before Tax (V-VI)	0.33	3.68	(0.02)	4.73	(3.13)	0.29
VIII Tax Expense	0.09	0.96	-	1.23	-	0.07
(a) Current Tax	0.09	0.96	-	1.23	-	0.07
(b) (Less):- MAT Credit	-	-	-	-	-	-
(c) Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(d) Deferred Tax (Asset)/Liabilities	-	-	-	-	-	-
IX Profit (Loss) for the period from continuing operations (VII-VIII)	0.24	2.72	(0.02)	3.50	(3.13)	0.22
X Profit/(loss) from discontinued operations						
XI Tax expenses of discontinued operations						
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)						
XIII A Profit(Loss) For Period Before Minority Interest						
XIII B Share Of Profit / Loss of Associates and joint ventures accounted for using equity method						
XIII C Profit/Loss Of Minority Interest						
XIV Profit (Loss) for the period (XIII A + XIII B + XIII C)						
XV Other Comprehensive Income						
a. i). Items that will not be reclassified to profit or loss						
ii). Income tax relating to items that will not be reclassified to profit or loss						
b. i). Item that will be reclassified to profit or loss						
ii). Income tax relating to items that will be reclassified to profit or loss						
Total Comprehensive income						
XVI Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)						
XVII Details of equity share capital						
Paid-up equity share capital	488.48	488.48	488.48	488.48	488.48	488.48
Face value of equity share capital (Per Share)	10.00	10.00	10.00	10.00	10.00	10.00
XIX Earnings per share						
(a) Earnings per share (not annualised for quarter ended)						
Basic earnings (loss) per share from continuing operation	0.00	0.06	(0.00)	0.07	(0.06)	0.00
Diluted earnings (loss) per share from continuing operation	0.00	0.06	(0.00)	0.07	(0.06)	0.00
(b) Earnings per share (not annualised for quarter ended)						
Basic earnings (loss) per share from discontinued operation	-	-	-	-	-	-
Diluted earnings (loss) per share from discontinued operation	-	-	-	-	-	-
(c) Earnings per share (not annualised for quarter ended)						
Basic earnings (loss) per share from continuing and discontinued operations	0.00	0.06	(0.00)	0.07	(0.06)	0.00
Diluted earnings (loss) per share continuing and discontinued operations	0.00	0.06	(0.00)	0.07	(0.06)	0.00

Notes on Financial Results:-

1	The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
2	The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circulars.
3	The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 10th February 2023.
4	The Statutory Auditors of the Company have carried out limited review of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

For Gujarat Inject Kerala Limited



Reena
Reena Mahatma
Non-Executive Director
DIN 02846012

Date :- 10-Feb-23
Place:- Vadodara



S. MANDAWAT & CO.
Chartered Accountants

913, Sahjanand Shopping Centre,
Opp. Rajasthan Hindi School,
Shahibaug Road, Ahmedabad-380004.
(M) 9426072909 E-mail : skmandwat@yahoo.co.in

Limited Review Report on quarterly Un-audited Standalone Financial Results of Gujarat Inject Kerala Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019

To,
The Board of Directors of
Gujarat Inject Kerala Limited,
SB-06, Paradise Complex,
Opp. M.S. University,
Sayajiganj, Vadodara – 390 005

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of M/s. Gujarat Inject Kerala Limited ("the Company"), for the quarter ended on 31st December, 2022 ("the statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: Ahmedabad
Place: 10/02/2023

For, M/s. S. Mandawat & Co.
Chartered Accountant
FRN: 118330W

CA Subhash Chandra Mandawat
Partner
UDIN: 23102708BGVQQA6696

